QUECTEL
16.5.2023 18:26:27 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces breaking ground for its new innovation Headquarter in Shanghai and also recently celebrated a significant milestone with the opening of its new Global Intelligent Manufacturing Center (GIMC) in Changzhou.
Delivering advanced IoT automation, the new GIMC facility features a fully functioning manufacturing production line that combines latest technologies, including edge intelligence, machine learning, robotics and machine vision solutions built with Quectel’s latest smart module technologies which significantly expands manufacturing capabilities to guarantee supply and reassure product quality for global customers. Designed and architected by a group of its own IoT experts, this state-of-the art IoT manufacturing center is equipped with the most advanced industrial automation technologies including:
- Fully automated warehouse storage system with 65,000 material cubicles, which can support 40 SMT lines material supply and operate 7x24 based on real-time workorders.
- End-to-end touchless process with Automatic Guided Vehicles to transport raw material to production lines, hand-over semi-products from SMT for testing and final packing with minimal manpower.
- 30 Fuji NXT-III SMT lines with Siemens MES monitoring system supporting production of up to 150 million modules per year.
- 85 Quectel Self Design Automatic Testing Stations with full testing log files onto each module produced.
- 40 Quectel Self Design Auto Inspection and Packing Systems.
The GIMC project started construction in September 2021 and will commence operation in 2023. The smart factory will further enhance Quectel’s production capabilities, strengthening its core competitiveness. The center occupies an area of 72,000 square meters, with a total construction space of 160,000 square meters. It is capable of manufacturing Quectel’s full range of modules, including 4G modules, 5G modules, smart modules, automotive grade modules, narrowband IoT modules, GNSS modules, Wi-Fi modules and antennas.
“Our new smart factory represents an important step toward the next generation of smart manufacturing and will guarantee both our product quality and production capacity, sufficient to meet various demanding requirements of our global customers,” said Patrick Qian, CEO of Quectel. “Applying IoT innovation to our own processes -- will not only help us enhance our industry leading quality -- it will also accelerate the expansion of the global IoT market and be a catalyst for the entire IoT eco-system.”
Quectel also recently broke ground for its new headquarters in Shanghai. “The new headquarter is designed to provide a modern, smart environment that makes it attractive for the best people to work, excel and innovate and that exceeds the highest standards in sustainability, health and wellness,” Mr. Qian continued.” It will host Quectel’s R&D center and IoT innovation showroom and will bring together some of the world’s greatest engineers and IoT leaders to accelerate innovation and drive the future of IoT”. The new headquarter of approximately 100,000 square meters will serve as a central hub for administrative and research and development functions but will also offer a wide range of amenities including sports facilities, conference spaces, outdoor gardens, catering services, and ample parking facilities. The company plans to officially inaugurate and begin operations at the new headquarters in 2025.
Founded in 2010, Quectel has consistently maintained rapid development and has become a leading global IoT provider of solutions covering cellular modules, Wi-Fi modules, smart modules, automotive modules, GNSS modules, antennas as well as connectivity and certification services.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005801/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom